Erratum to: Hypocitraturia Is an Untoward Side Effect of Synthetic Human Parathyroid Hormone (hPTH) 1-34 Therapy in Hypoparathyroidism That May Increase Renal Morbidity: HYPOCITRATURIA AS SIDE EFFECT OF HPTH 1-34 THERAPY IN HYPOPARATHYROIDISM (Journal of Bone and Mineral Research, (2018), 33, 10, (1741-1747), 10.1002/jbmr.3480)

The authors have informed the Editors that after publication they found errors in the analysis and presentation of some clinical laboratory data and requested that a revision to one statement be published as an Erratum. The clinical laboratory data collected during a multi-day in-patient visit reported lab values that were recorded after the first treatment with hPTH. These values should not have been factored into the baseline labs, because they are not true reflections of subjects' pre-hPTH physiology. The authors also re-assessed other laboratory parameters in the study database, resulting in additional corrections. This reanalysis resulted in nominal changes to a few summary statistics, with only one substantive change to the results; namely, blood phosphate now significantly changes over time (p = 0.018) with a significant decrease from baseline to both the last visit on hPTH (mean change −0.30 ± 0.12 mg/dL, p = 0.013) and the post-hPTH follow-up visit (−0.36 ± 0.13 mg/dL, 0.005). Other value changes are inconsequential, therefore the change in blood phosphate is the focus of this Erratum. The second paragraph, page 1743, lines 24-35 should be replaced with the following statement: At baseline, mean fasting blood levels of calcium and phosphate were 8.18 ± 0.12 mg/dL (2.04 ± 0.03 mmol/L) and 4.88 ± 0.11 mg/dL (1.58 ± 0.04 mmol/L), respectively. The blood calcium was not significantly different at the target time-point comparisons. The blood phosphate, however, decreased significantly from baseline at both the last visit on hPTH (mean at visit value 4.60 ± 0.09; lsmean change −0.30 ± 0.12 mg/dL, p = 0.013) and the post-hPTH follow-up visit (mean at visit value 4.53 ± 0.12; lsmean change −0.36 ± 0.13 mg/dL, 0.005). While a slight downward trend in mean tubular phosphate reabsorption was observed after starting hPTH and at the follow-up visit, the differences were not statistically significant. After review of the documentation, the Editor-in-Chief recommended that this Erratum be published. The authors regret the mistakes and apologize for any confusion this might have caused. Reference Gafni RI, Langman, CB, Guthrie LC, Brillante, BA, James, R, Yovetich, NA, Boyce, AM, Collins, MT, Hypocitraturia is an untoward side effect of synthetic human parathyroid hormone (hPTH) 1-34 therapy in hypoparathyroidism that may increase renal morbidity. J Bone Miner Res 2018;33(10):1741–1747.